65, respectively, P < 0.05). Our results showed that the increased percentage of myofibre type I and high expression of calpain 3 and PGC-1 alpha are positively related to meat tenderness. The results provide useful data for meat tenderness selection in pig breeding. (C) 2012 Elsevier B.V. All rights reserved.”
“Background Mercaptopurine and azathioprine (AZA) are efficacious in treating IBD. 6-tioguanine (6-TGN) levels correlate with therapeutic efficacy, whereas high 6-methylmercaptopurine (6-MMP) levels are associated with hepatotoxicity and myelotoxicity. Some IBD patients exhibit dose-limiting preferential 6-MMP production, Fedratinib mouse which may lead to undesired side effects and impact efficacy. Aim To review
the outcomes of thiopurine split-dosing in patients with preferential 6-MMP metabolism. Methods A retrospective chart review of 179 IBD patients treated at the Cedars-Sinai IBD Center with AZA or mercaptopurine was performed. Preferential 6-MMP metabolisers with 6-MMP levels greater than 7000 pmol/8 x 108 erythrocytes who underwent split-dosing were identified and assessed for biochemical and clinical responses to these dose modifications. Results A total of 20 of 179 patients met the criteria for preferential 6-MMP metabolism and underwent thiopurine split-dosing. Dividing the total daily thiopurine CDK and cancer dose led to a reduction
in 6-MMP levels (11785 vs. 5324 pmol/8 x 108 erythrocytes; P < 0.0001) without negatively affecting clinical disease activity or 6-TGN levels (239 vs. 216 pmol/8 x 108 erythrocytes; P = N.S.) and led to resolution of 6-MMP associated side effects (elevated transaminases,
leucopenia and flu-like symptoms) in all but two patients. After mean follow-up of 36 months, 12 patients remained in clinical remission on split-dose mercaptopurine. Five of the remaining eight patients escalated to anti-TNF therapy, two progressed to surgery, and one switched to tioguanine therapy. Conclusion Split-dose administration of mercaptopurine/AZA represents an alternative option in IBD patients with preferential 6-MMP metabolism who might otherwise require steroid exposure or escalation of therapy.”
“Intravascular stenting has emerged as the primary treatment for vascular diseases and has received great attention from the selleck inhibitor medical community since its introduction two decades ago. The endovascular self-expanding stent is used to treat peripheral artery diseases; however, once implanted, these stents suffer from various cyclic motions caused by pulsatile blood pressure and daily activities. Due to this challenging environment, fatigue performance has become a critical issue for stent design. In this paper, a simple yet intriguing concept of stent design aimed at enhancing pulsatile fatigue life is investigated. The concept of this design is to shift the highly concentrated stresses/strains away from the crown and re-distribute them along the stress-free bar arm by tapering its strut width.